J&J nabs ac­cel­er­at­ed FDA OK for one of their top late-stage drugs

Score one new po­ten­tial block­buster OK for J&J.

The FDA of­fered a quick stamp of ap­proval for their sol­id tu­mor drug erdafi­tinib Fri­day af­ter­noon, al­low­ing the phar­ma gi­ant to put a check­mark by one of their top pipeline projects. Ex­ecs high­light­ed this drug close to 2 years ago as one of the top 11 ther­a­pies they were steer­ing through late-stage tri­als. And it’s a key part of an R&D plan aimed at re­viv­ing sales growth.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER